Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. META
9. AMC
10. ACN

Go back to Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization
(NASDAQ: BJDX) Delayed: 0.91 -0.01 (1.09%)
Previous Close $0.92    52 Week High $ 
Open $0.93    52 Week Low $ 
Day High $0.94    P/E N/A 
Day Low $0.90    EPS $ 
Volume 214,781